Intravenous Clexane (Enoxaparin) Uses
Intravenous enoxaparin is primarily used as adjunctive anticoagulation during percutaneous coronary intervention (PCI) in acute coronary syndromes, and as supplemental dosing in specific clinical scenarios following fibrinolytic therapy for ST-elevation myocardial infarction (STEMI).
Primary Clinical Indications
PCI Support in Acute Coronary Syndromes
For patients undergoing PCI who have not received prior anticoagulation, IV enoxaparin (0.5-0.75 mg/kg bolus) provides effective procedural anticoagulation 1, 2, 3. The 0.5 mg/kg dose reduces bleeding complications compared to unfractionated heparin while maintaining similar efficacy, whereas 0.75 mg/kg yields bleeding rates comparable to UFH with more predictable anticoagulation levels 4, 3.
Supplemental Dosing After Fibrinolytic Therapy
When patients receiving subcutaneous enoxaparin with fibrinolytic therapy require PCI, supplemental IV dosing is critical based on timing:
- If last subcutaneous dose was within 8 hours: No additional enoxaparin needed 1, 2
- If last subcutaneous dose was 8-12 hours prior: Give 0.3 mg/kg IV bolus 1, 5, 2, 5
- If last dose was >12 hours prior: Full procedural anticoagulation required 1, 2
This timing-based approach is particularly important for patients >75 years who don't receive the initial IV bolus with fibrinolytic therapy per the EXTRACT-TIMI 25 protocol 5.
Elective PCI
For stable patients undergoing elective PCI without upstream anticoagulation, a single IV bolus of 0.5-0.75 mg/kg can be administered at the time of the procedure 3. The lower dose (0.5 mg/kg) is associated with reduced bleeding while the higher dose (0.75 mg/kg) provides anticoagulation levels similar to UFH 4.
Key Clinical Advantages
The IV route offers several practical benefits over subcutaneous administration in acute settings:
- Immediate onset of action for time-sensitive procedures
- More predictable anticoagulation levels compared to UFH, with 79-92% of patients reaching target levels versus only 20% with UFH 4
- Reduced bleeding risk at the 0.5 mg/kg dose compared to standard UFH dosing 4
- No need for aPTT monitoring unlike UFH
Important Caveats
Do not use enoxaparin as monotherapy for primary PCI in STEMI - while it can be used, the evidence base is strongest for its use after fibrinolytic therapy or in elective settings 1, 2.
Avoid in severe renal insufficiency (CrCl <30 mL/min) - enoxaparin shows significantly higher bleeding rates in moderate to severe renal impairment despite dose adjustments 6.
Transitioning between anticoagulants requires careful timing - switching from enoxaparin to UFH or bivalirudin is only safe if the last enoxaparin dose was >12 hours prior to PCI 1, 2.
The evidence supporting IV enoxaparin comes primarily from large randomized trials like EXTRACT-TIMI 25 and STEEPLE, with consistent guideline support from ACC/AHA, ESC, and Canadian Cardiovascular Society 1, 6, 7, 2, 8.